| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Switzerland Pharmaceuticals and Healthcare Report Q2 2010
Market |
Healthcare and Medical |
Report Type |
Market Research |
Country |
Switzerland |
Published |
11 March 2010 |
Number of Pages |
75 |
Download |
|
Immediate |
|
Publisher |
Business Monitor International |
In our Business Environment Ratings for Q210, Switzerland remains placed second, having lost its pole position to Germany in Q409. Globally, the country is no longer within the top five, now placing 6th, between Australia and Belgium, out of the 71 markets surveyed in our pharmaceutical universe. Switzerland may fall further down the world ranking as large, high-growth emerging markets such as Brazil and China become more alluring to multinational drugmakers in the medium to longer term. Switerland’s drug market was valued at CHF5.9bn (US$5.5bn) in 2008, with this figure rising to CHF6.1bn (US$5.6bn) in 2009, despite the flat performance of the over-the-counter (OTC) segment. According to IMS figures, the market rose by 3.4% in value in 2009, reaching CHF4.9bn at exmanufacturers’ prices. The rate of increase was slower than in previous years (some 5.5% in 2008), as the higher uptake of generics played a major role in market development. In fact, hospital-used generics increased by 3.9% y-o-y in value to CHF449mn in 2009. Through to 2014, we forecast that the value of the Swiss pharmaceutical market will post a compound annual growth rate (CAGR) of 2.00% in local currency, reaching CHF6.7bn (US$5.4bn), with the following five years proving to be even more challenging.
In the meantime, the Swiss government recently approved an amendment to the law regulating the dispensing and authorisation of medicines in Switzerland (Heilmittelgesetz). A hearing is currently in progress, with the outcome potentially to ban doctors from dispensing medicines in their surgeries. Presently, across 17 of the 26 Swiss cantons, this practice of self-dispensation is partly or wholly permitted, though it is already banned in the remaining nine. The new legislation also envisages a lowering of the profit margin from the current 15% to 12%, which would clearly have an impact on the performance of the prescription segment. On a positive note, the changes would be welcomed by the country’s retail pharmacy industry, as it would significantly reduce competition.
In terms of major industry news, US-based Cephalon is poised to acquire Swiss generic drugmaker Mepha AG and its subsidiaries from the family of the late German billionaire Adolf Merckle, for US$590mn. French Sanofi-Aventis, through its Winthrop generics arm (which has a limited presence in Switzerland), had previously been linked with the purchase of Mepha. While the company commands the largest share of the Swiss generic medicines market – alongside Novartis’s Sandoz – Mepha is also focused on creating improved and innovative medicine dosage formulations and on the marketing of branded and non-branded generic drugs. Generally speaking, however, the Swiss generics market is considered relatively unattractive to foreign players compared with its Western European counterparts. The Mepha-Sandoz duopoly has been highlighted as the key reason for this situation, despite considerable growth in both volume and value terms in the generics market in recent years, as well as a positive longer-term outlook for the segment, which is forecast to account for over 12% of the total market by 2014, up from less than 10% presently.
Last Viewed
Switzerland Pharmaceuticals and Healthcare Report Q2 2010Time Warner Inc - 2009 Fortune Global 500 Company Snapshot
Technology Partners - Clean Technology - Investment Profile
Research Report of Investment in China's Tire Industry, 2009
Electronics For Imaging, Inc. - Financial Analysis Review
Healthcare and Medical Company Profiles
Healthcare and Medical Company Profiles contain up to date financial, strategic, operational, SWOT analysis and product information on the activities of thousands of healthcare and medical companies.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website. If a sale is made from your visitor, you earn commission (a fixed percentage of the price of a product).
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Genium Bionic Prosthetic System Represents the First Intuitive Knee
AdCare continues nursing facilities acquisitions strategy
AdCare Purchases US$27.3Mn Nursing Facilities in Arkansas to Drive Strong Revenue Growth
Micromet to Develop Blinatumomab with the National Cancer Institute
AstraZeneca to Develop Targacept’s Product Candidate AZD1446 as a Treatment for Alzheimer’s
Market Insights
Currently there are no Market Insights in this sector.
